Metrics as of 10/17/2026, 03:32 AM (Berlin time), refresh in progress.
SkyAI Stock
SkyAI, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Paul K. Danner
- Employees
- 55
- Market cap
- $54 M
- IPO
- 14/04/2022
- Web
- skyai.co
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, provides smart-safety syringe products to the healthcare industry. Its product lines focus on providing waste capabilities that incorporate syringe technologies. The company, through a digital asset treasury strategy, focuses on…
SkyAI stock: price history
1D
-3.8%
1W
-6.3%
1M
-1.1%
6M
-45.9%
YTD
-12.8%
1Y
-53.4%
2Y
-99.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~44% stronger price swings than usual
Ask the agents about SkyAI
Analyst assessment of SkyAI
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 09/05/2023
SkyAI stock metrics
P/E
-0.1
P/B
0.58
EV/EBITDA
-0.11
RETURN ON EQUITY
-14.8%
NET MARGIN
-1,002.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
65.3%
FLOAT SHARES
27,644,754
AVG. DAILY VOLUME (30D)
274,879
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about SkyAI stock
What does SkyAI do?
SkyAI, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Paul K. Danner, the company employs around 55 people.
The IPO was on 14/04/2022; the stock trades on NASDAQ under the ticker STSS.
What do analysts say about SkyAI stock?
1 analysts rate the stock, the consensus is Buy (as of 09/05/2023).
This is an external assessment, not a statement by Market Jury.
When does SkyAI report next?
Around past earnings, price swings were roughly 44% stronger than usual.
Does SkyAI pay a dividend?
No, SkyAI currently does not pay a dividend.
Which stocks are comparable to SkyAI?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get SkyAI stock analyzed?
Clicking "Analyze stock" lets five strategies assess SkyAI against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.